BI-749327 is a potent and selective small molecule inhibitor targeting the p38α mitogen-activated protein kinase (MAPK) pathway. This compound is primarily used in research settings to investigate inflammatory and immune-mediated diseases. Due to its high selectivity, it helps suppress pro-inflammatory cytokine production, making it a valuable tool in studying conditions such as rheumatoid arthritis, chronic obstructive pulmonary disease (COPD), and other inflammatory disorders.

It is also employed in oncology research, where p38 signaling plays a role in tumor progression and resistance to therapy. By modulating this pathway, BI-749327 aids in understanding how p38 inhibition affects cancer cell survival and response to chemotherapeutic agents. Its use is largely confined to preclinical studies, supporting target validation and mechanistic exploration rather than clinical application.